Research progress in CDK4/6 inhibitors in neoadjuvant therapy of HR-positive HER2-negative breast cancer

doi:10.3781/j.issn.1000-7431.2022.2111-0864

PDF(751 KB)

Tumor ›› 2022, Vol. 42 ›› Issue (12) : 835-844. DOI: 10.3781/j.issn.1000-7431.2022.2111-0864

Review

Research progress in CDK4/6 inhibitors in neoadjuvant therapy of HR-positive HER2-negative breast cancer

{{article.zuoZhe_EN}}

Author information +

History +

HeighLight

Abstract

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2022, 42(12): 835-844 https://doi.org/10.3781/j.issn.1000-7431.2022.2111-0864

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

Funding

RIGHTS & PERMISSIONS

PDF(751 KB)

Accesses

Citation

Detail

Sections

Recommended

Received	Accepted	Published
2021-11-11	2022-06-16	2022-12-25
Issue Date
2022-12-25

Please choose a citation manager

Content to export

HeighLight

Abstract

Key words

QR code of this article

Cite this article

{{custom_sec.title}}

{{custom_sec.title}}

References

References

{{custom_fnGroup.title_en}}

Footnotes

{{custom_ack.title_en}}

Funding

RIGHTS & PERMISSIONS